Prisma's elegant chemistry to unlock unbiased, single-molecule protein sequencing!
The functional drivers of biology,
Proteins are the final frontier to understanding life itself.
Prisma Bio, a breakthrough protein sequencing tools company, is digitizing the proteome to unveil novel drug targets, disease mechanisms, and biomarkers to improve patient outcomes.
The Digital Proteome: Unveiling the Final Frontier of Biomedical Research
Prisma is advancing breakthrough protein sequencing technologies to unveil the true functional drivers of biology, catalyze the AI revoluztion in biology, and transform human health.
Imagine a world where we can resolve every protein within a sample, revealing its identity and quantity with stunning resolution.
This is the future Prisma is building with unbiased, single-molecule protein sequencing, a revolutionary approach that analyzes proteins for hypothesis free discovery. Prisma is powering
This video dives into Prisma's elegant protein sequencing technology. Our patented, Universal Recognizer is a single, small molecule dye that binds directly to the N-terminus of proteins and produces a distinct optical fingerprint for each amino acid and post-translational modification. Combined with our proprietary and cutting-edge, light-based sequencing approach, Prisma generates accurate amino acid sequences to enable unbiased, proteome-scale identification and quantification of proteins at the single-molecule level.
Sammy Datwani, PhD
Co-Founder & CEO
Aaron Beeler, PhD
Co-Founder
Chemistry
Craig Hetherington, PhD
Optics
Michael Levitt, PhD Nobel laureate
Proteomics
Andrew Emili, PhD
Co-Founder
Proteomics
Amanda Cashin, PhD
Co-Founder
NGS Tools
Jake LaPorte, PhD
Co-Founder
BD
David Duffy, PhD
R&D
Bob Kain
Engineering
Anderson Chen, PhD
Co-Founder
Optics
Carlo Rizzuto, PhD
Alex Mayweg, PhD
Follow us on LinkedIn for the latest
Contact us to learn more and explore how we might work together to tackle the final frontier of biology